ISSN 2168-622X, 2168-6238
85 papers in the library · 7,976 citations · publishing 2013-2026
JAMA Psychiatry February 12, 2025 Brian S. Barnett, Roger D Weiss, Gerard Sanacora 7 citations
This Viewpoint discusses challenges related to ketamine use within psychiatry and offers recommendations for optimizing patient safety.
JAMA Psychiatry February 1, 2025 Daniel T. Myran, Michael Pugliese, Jennifer Xiao et al. 23 citations
Interest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association. To examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD)....
JAMA Psychiatry December 10, 2024 Ethan G. Dutcher, Andrew D. Krystal 5 citations
This secondary analysis of a randomized clinical trial examines the association between treatment expectancies and the relative efficacy of psilocybin compared with escitalopram for major depressive disorder.
JAMA Psychiatry November 6, 2024 PhD K.JustonOsborne, PhD DeannaM.Barch, PhD JoshuaJ.Jackson et al.
Importance Adolescent cannabis use has been consistently posited to contribute to the onset and progression of psychosis. However, alternative causal models may account for observed associations between cannabis use and psychosis risk, including shared vulnerability for both cannabis use and psychosis or efforts to self-medicate distress from psychosis spectrum symptomology. Objective To test 3...
JAMA Psychiatry November 1, 2024 Ioana Alina Cristea, Pim Cuijpers, Joar Øveraas Halvorsen
This Viewpoint discusses the critical yet overlooked role of the psychotherapy component in assessing the validity of the trials of midomafetamine/3,4-methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder.
JAMA Psychiatry September 4, 2024 Marianna Graziosi, Jared T. Hinkle, Sandeep M. Nayak et al. 126 citations
Importance A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications. Objective To assess adverse events (AEs) associated with classic psychedelics, particularly serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric evaluation. Data Sources The...
JAMA Psychiatry July 1, 2024
Importance: Although grief-focused cognitive behavior therapies are the most empirically supported treatment for prolonged grief disorder, many people find this treatment difficult. A viable alternative for treatment is mindfulness-based cognitive therapy. Objective: To examine the relative efficacies of grief-focused cognitive behavior therapy and mindfulness-based cognitive therapy to reduce...
JAMA Psychiatry April 10, 2024 Mason Marks, Rebecca Weintraub Brendel, Carmel Shachar et al. 46 citations
Importance: Interest in administering psychedelic agents as mental health treatment is growing rapidly. As drugmakers invest in developing psychedelic medicines for several psychiatric indications, lawmakers are enacting legal reforms to speed access globally, and health agencies are preparing to approve these treatments. Meanwhile, US states, such as Oregon and Colorado, are making...
JAMA Psychiatry April 10, 2024 Eiko I. Fried, Ioana A. Cristea, Florian Naudet 2 citations
To the Editor According to the study protocol, the recently published study by Aaronson et al1 was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns.
JAMA Psychiatry April 10, 2024 Scott T Aaronson, Andrew van der Vaart, Harold A Sackeim
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry April 10, 2024 Paul S. Appelbaum
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry April 1, 2024 Nina A Cooperman, Shou-En Lu, Adam W. Hanley et al. 39 citations
Methadone treatment (MT) fails to address the emotion dysregulation, pain, and reward processing deficits that often drive opioid use disorder (OUD). New interventions are needed to address these factors. To evaluate the efficacy of MT as usual (usual care) vs telehealth Mindfulness-Oriented Recovery Enhancement (MORE) plus usual care among people with an OUD and pain. This study was a...
JAMA Psychiatry March 13, 2024 Otto Simonsson, Miriam A. Mosing, Walter Osika et al. 41 citations
Importance While psychedelic-assisted therapy has shown promise in the treatment of certain psychiatric disorders, little is known about the potential risk of psychotic or manic symptoms following naturalistic psychedelic use, especially among adolescents. Objective To investigate associations between naturalistic psychedelic use and self-reported psychotic or manic symptoms in adolescents...
JAMA Psychiatry January 3, 2024 Samuel T. Wilkinson, Joseph J Palamar, Gerard Sanacora 41 citations
This Viewpoint discusses changes in the use of ketamine as a medical therapeutic and a recreational substance, the potential risks of use, and the need for increased research and surveillance.
JAMA Psychiatry 2024 Claire A Walsh, Lauren Gorfinkel, Dvora Shmulewitz et al. 24 citations
Renewed interest in the clinical potential of hallucinogens may lead people with depression to a generally more positive view of the use of lysergic acid diethylamide (LSD). Therefore, past-year LSD use among people with depression may be increasing in prevalence. To assess time trends in the prevalence of past-year nonmedical LSD use by past-year major depression status and the variation in...
JAMA Psychiatry December 6, 2023 Tammy Miller, Jeffrey LaPratt, Kimberly Swartz et al. 101 citations
Importance Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. Objective To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode. Design, Setting, and...
JAMA Psychiatry December 6, 2023 David B. Yaden, Natalie Gukasyan, Sandeep M. Nayak 2 citations
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
JAMA Psychiatry December 1, 2023 Sanjay J. Mathew, Manish K. Jha, Amit Anand 8 citations
This Viewpoint examines key issues stemming from several recent reports of electroconvulsive therapy (ECT) vs ketamine for improving depressive symptoms in treatment-resistant depression (TRD).
JAMA Psychiatry December 1, 2023 Chittaranjan Andrade
This Viewpoint discusses ketamine and its new and experimentally investigated on- and off-label indications that span different medical disciplines.
JAMA Psychiatry September 1, 2023 Luana Colloca, Sina Nikayin, Gerard Sanacora
This Viewpoint explores how expectations influence outcomes of psychedelic drug therapy.
JAMA Psychiatry July 26, 2023 Nora D. Volkow, J. Gordon, Eric M. Wargo
This Viewpoint discusses the potential promise of the therapeutic use of psychedelics for mental illness and substance use disorders, acknowledging many open research questions and unique challenges with these substances.
JAMA Psychiatry July 1, 2023 Roman Palitsky, Deanna M Kaplan, Caroline Peacock et al. 86 citations
Mounting evidence supports the role of spiritual, existential, religious, and theological components in mediating psychedelic-assisted therapy, yet integration of these elements into the clinical setting is lagging. Although psychedelic-assisted therapy commonly produces spiritually, existentially, religiously, or theologically relevant experiences for patients, these have not been...
JAMA Psychiatry June 1, 2023 Vikas Menon, Natarajan Varadharajan, Abdul Faheem et al. 50 citations
ImportanceThe relative efficacy of ketamine and electroconvulsive therapy (ECT) in adults with major depressive episode (MDE) needs clarification.ObjectiveTo compare depression rating outcomes with ketamine vs ECT in adults with MDE and to compare response and remission rates, number of sessions to response and remission, and adverse effects.Data SourcesTwo investigators independently...
JAMA Psychiatry May 31, 2023 Abigail E. Calder, Gregor Hasler 14 citations
This Viewpoint proposes methods for optimizing patient and therapist safety during psychedelic-assisted psychotherapy.
JAMA Psychiatry May 1, 2023 Clara Strauss, Anna-Marie Bibby-Jones, Fergal Jones et al.
Depression is prevalent. Treatment guidelines recommend practitioner-supported cognitive behavioral therapy self-help (CBT-SH) for mild to moderate depression in adults; however, dropout rates are high. Alternative approaches are required. To determine if practitioner-supported mindfulness-based cognitive therapy self-help (MBCT-SH) is superior to practitioner-supported CBT-SH at reducing...